4D Molecular Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

4D Molecular TherapeuticsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -25.3% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 1.9% pro Jahr.

Wichtige Informationen

-25.3%

Wachstumsrate der Gewinne

24.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	1.9%
Eigenkapitalrendite	-17.4%
Netto-Marge	-511.2%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely

Aug 06

Newsflash: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Analysts Have Been Trimming Their Revenue Forecasts

Jun 28

4D Molecular inks collaboration deal on machine learning technology

May 04

We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth

May 04

Have Insiders Been Buying 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares?

Mar 11

Aufschlüsselung der Einnahmen und Ausgaben

Wie 4D Molecular Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:FDMT Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	20	-105	39
31 Dec 23	21	-101	36
30 Sep 23	22	-96	34
30 Jun 23	2	-111	33
31 Mar 23	2	-110	33
31 Dec 22	3	-107	33
30 Sep 22	2	-105	32
30 Jun 22	3	-102	32
31 Mar 22	17	-81	31
31 Dec 21	18	-71	28
30 Sep 21	17	-67	28
30 Jun 21	23	-52	23
31 Mar 21	12	-60	19
31 Dec 20	14	-57	17
30 Sep 20	17	-52	16
30 Jun 20	10	-61	16
31 Mar 20	8	-54	15
31 Dec 19	7	-49	14
30 Sep 19	9	-35	10
30 Jun 19	13	-21	9
31 Mar 19	14	-15	8
31 Dec 18	14	-10	6
31 Dec 17	6	-11	3

Qualität der Erträge: FDMT ist derzeit unrentabel.

Wachsende Gewinnspanne: FDMT ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: FDMT ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 25.3% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von FDMT verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: FDMT ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: FDMT hat eine negative Eigenkapitalrendite (-17.41%), da es derzeit unrentabel ist.

4D Molecular Therapeutics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis At 47Th European Cystic Fibrosis Conference

First quarter 2024 earnings released: US$0.66 loss per share (vs US$0.88 loss in 1Q 2023)

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc., Annual General Meeting, May 21, 2024

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Price target increased by 9.3% to US$54.75

4Dmt Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

Consensus revenue estimates decrease by 33%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics, Inc. Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Chief Medical Officer exercised options and sold US$354k worth of stock

New major risk - Shareholder dilution

4D Molecular Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $299.999626 million.

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

4D Molecular Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

New major risk - Share price stability

Price target increased by 9.6% to US$37.00

4D Molecular Therapeutics Presents Positive Interim Data from Randomized Phase 2 Prism Clinical Trial of Intravitreal 4D-150

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Co-Founder notifies of intention to sell stock

4D Molecular Therapeutics Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4D Molecular Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD

Co-Founder notifies of intention to sell stock

Insufficient new directors

Consensus revenue estimates increase by 96%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis At 2023 NACFC

4D Molecular Therapeutics, Inc. Announced Alignment with the U.S. Food and Drug Administration on A Plan to Lift the Clinical Hold on the Phase 1/2 Inglaxa Clinical Trial in the United States

4D Molecular Therapeutics, Inc. Announces Executive Changes

Price target decreased by 14% to US$33.50

4D Molecular Therapeutics, Inc. Announces First Patient Enrolled in 4D-150 Phase 2 Spectra Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in Prism Clinical Trial in Wet AMD

Consensus revenue estimates increase by 41%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023

Consensus revenue estimates increase by 163%

4D Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting

4Dmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society (Ecfs) 46Th Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Price target increased by 8.3% to US$41.17

Full year 2022 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

Price target increased by 8.1% to US$38.00

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

4D Molecular Therapeutics, Inc. Announces Updates on Clinical Pipeline and Additional Preclinical Programs

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$85k worth of stock

Price target increased to US$23.80

High number of new directors

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from On-Going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released November 14, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

4D Molecular Therapeutics, Inc. Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease At NACFC 2022

High number of new directors

High number of new directors

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell 2000 Growth Index

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Price target decreased to US$21.00

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$32.00